1. In Vitro Selection of Remdesivir-Resistant SARS-CoV-2 Demonstrates High Barrier to Resistance.
- Author
-
Checkmahomed L, Carbonneau J, Du Pont V, Riola NC, Perry JK, Li J, Paré B, Simpson SM, Smith MA, Porter DP, and Boivin G
- Subjects
- Adenosine Monophosphate analogs & derivatives, Adenosine Monophosphate chemistry, Alanine analogs & derivatives, Alanine metabolism, Antiviral Agents chemistry, Humans, SARS-CoV-2, COVID-19 Drug Treatment
- Abstract
In vitro selection of remdesivir-resistant severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) revealed the emergence of a V166L substitution, located outside of the polymerase active site of the Nsp12 protein, after 9 passages of a single lineage. V166L remained the only Nsp12 substitution after 17 passages (10 μM remdesivir), conferring a 2.3-fold increase in 50% effective concentration (EC
50 ). When V166L was introduced into a recombinant SARS-CoV-2 virus, a 1.5-fold increase in EC50 was observed, indicating a high in vitro barrier to remdesivir resistance.- Published
- 2022
- Full Text
- View/download PDF